Microporous polysaccharide hemospheres reduce blood loss in total hip arthroplasty

doi:10.3969/j.issn.2095-4344.2015.12.013

Abstract

Abstract:

BACKGROUND: In foreign animal experiments and clinical reports, microporous polysaccharide hemospheres are characterized as good hemostatic effect, no delayed bleeding, good biocompatibility, and no adverse reactions in the body.
OBJECTIVE: To assess the efficacy and safety of microporous polysaccharide hemospheres on reducing blood loss after unilateral total hip arthroplasty.
METHODS: Totally 98 patients who received unilateral total hip arthroplasty due to femoral neck fractures, 39 males and 59 females, aged 61-77 years, were randomly divided into two groups: test group, treated with 1g microporous polysaccharide hemospheres before suture of wound; control group, treated with electric coagulation hemostasis before suturing. Drainage tubes were placed in the two groups. Hemoglobin, blood loss, allogeneic transfusion rate, drainage volume, coagulation index and incidence of deep venous thrombosis of the lower limbs were compared.
RESULTS AND CONCLUSION: The total blood loss, drainage volume, and transfusion rate in the test group were significantly lower than those in the control group (P < 0.01), but there were no differences in D-dimer, platelet count, activated partial thromboplastin time and international normalized ratio between the two groups. One case of each group developed deep venous thrombosis of the lower limbs, and no significant difference was in the incidence of deep venous thrombosis between the two groups. No infection occurred. These findings indicate that microporous polysaccharide hemospheres that are safe, effective and convenient can reduce the visible and hidden blood loss after unilateral total hip arthroplasty．

中国组织工程研究杂志出版内容重点：生物材料；骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性；组织工程

全文链接：

Key words: Arthroplasty, Replacement, Hip, Hemostasis, Blood Platelets

CLC Number:

R318

Liu Tian-sheng, Wang Qi, Wang Hao, Liu Ai-peng, Ma Jin-chao. Microporous polysaccharide hemospheres reduce blood loss in total hip arthroplasty[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(12): 1872-1877.

Figures/Tables 2

References

[1] Alshryda S,Mason J,Sarda P,et al.Topical (intra-articular) tranexamic acid reduces blood loss and transfusion rates following total hip replacement: a randomized controlledtrial (TRANX-H).J Bone Joint Surg Am.2013;95(21):1969-1974.
[2] Bruce W,Campbell D,Daly D,et al.Practical recommendationsfor patient blood management and the reduction of perioperative transfusion in joint replacement surgery. ANZ J Surg.2013;83(4):222-229.
[3] Zhao J,Li J,Zheng W,et al.Low Body Mass Index and BloodLoss in Primary Total Hip Arthroplasty: Results from 236Consecutive Ankylosing Spondylitis Patients. Biomed Res Int.2014;2014:742393.
[4] Sehat KR,Evans RL,Newman JH.Hidden blood loss following hip and knee arthroplasty. Correct management of blood loss should take hidden loss into account.J Bone Joint Surg Br. 2004;86(4):561-565．
[5] Liu X,Zhang X,Chen Y,et al.Hidden blood loss after total hip arthoplasty.The J Arthroplasty.2011;26(7):1100-1105．
[6] Murat FJ,Ereth MH,Dong Y,et al.Evaluation of microporous polysaccharide hemospheres as a novel hemostatic agent in open partial nephrectomy: favorable experimental results in the porcine model.J Urol.2004;172:1119-1122.
[7] Tschan CA,Nie M,Schwandt E,et al.Safety and efficacy of microporous polysaccharide hemospheres in neurosurgery. Neurosurgery.2011;69(1 Suppl Operative): 49-63.
[8] Tan SR,Tope WD.Effectiveness of microporous polysaccharidehemispheres for achieving hemostasis in mohs micrographic surgery. Dermatol Surg.2004;30(6): 908-914.
[9] Ereth MH,Dong Y,Schrader LM,et al.Microporous polysaccharidehemospheres do not enhance abdominal infection in a rat modelcompared with gelatin matrix.Surg Infect (Larchmt).2009;10(3):273-276.
[10] Rajaqopal P,Hakim N.The use of a powdered polysaccharide hemostat(HemoStase) in live donor nephrectomies controls bleeding and reduces postoperative complications.Transplant Proc.2011;43(2):424-426．
[11] Nunez-Nateras R,Hurd KJ,Ferrigni EN,et al.Athermal nerve sparingrobot-assistedradical prostatectomy: initial experience withmicroporous polysaccharide hemospheres as a topical hemostatic agent.World J Urol.2013;31(3):523-527．
[12] 王白石,杨红岩,晏晓青,等.微孔多聚糖材料用于体表创腔止血效果评价[J].医疗卫生装备,2012,33(4):80-81.
[13] 杜宝堂.利用植物淀粉经交叉乳化制备术中止血材料的方法：中国，201110073208.2 [P].2013-07-17.
[14] 史跃,杜宝堂,何远清,等.多微孔多聚糖止血粉应用于软组织创伤性出血[J].中国组织工程研究,2014,18(3):406-411.
[15] Antisdel JA,West-Denning JL,Sindwani R.Effect of microporous polysaccharide hemospheres(MPH) on bleeding after endoscopic sinus surgery:Randomized controlled study.Otolaryngol Head Neck Surg.2009;141(3):353-357.
[16] Humphreys MR,Castle EP,Andrews PE,et al.Microporous polysaccharide hemospheres for management of laparoscopi crocar injury to the spleen. Am J Surg.2008;195(1):99-103.
[17] Emmez H,Tonge M,Tokgoz N,et al.Radiological and histopathological comparison of microporous polysaccharide hemospheres and oxidized regenerated cellulose in the rabbit brain: a study of efficacy and safety.Turk Neurosurg.2010; 20(4):485-491.
[18] Ereth MS,Ibonga J,Oliver W,et al.Microporous polysaccharide hemospheres do not inhibit bone healing compared to bonewax or microfibrillar collagen.Othopedics. 2008;31(3): 222.
[19] Gavriliuk BK,Gavriliuk VB.Nanocomposite regeneration systems for wound healing.Biofizika.2011;56(6):1138-1141.
[20] 曹玮,陈蕾,唐鸿波.局部应用微孔多聚糖微粒对创面愈合影响的初步研究[J].中华损伤与修复杂志(电子版),2012,7(6):11-14.
[21] Lemaire R.Strategies for blood management in orthopaedic and trauma surgery.J Bone Joint Surg Br.2008;90:1128-1136.
[22] Kheirabadi B.Evaluation of topical hemostatic agents for combat wound treatment.US Army Med Dep J.2011:25-37．
[23] Casati V,Romano A,Novelli E,et al.Tranexamic acid for trauma. Lancet.2010;376(9746):1049-1050.
[24] Abzaeva KA,Voronkov MG,Zhilitskaya LV,et al.Hemostatic and antimicrobial activities of metallic salts of polyacrylic acid with group I metals.Dokl Biochem Biophys.2010;432:131-132.
[25] Crean S,Michels SL,Moschella K,et al.Bovine thrombin safety reporting:an example of study design and publication bias.J Surg Res.2010;158:77-86.
[26] 张少锋,洪加源.医用生物可吸收止血材料的研究现状与临床应用[J].中国组织工程研究,2012,16(21):3941-3944.
[27] 邓明武,贺德.局部止血材料在普通外科手术中的应用研究进展[J].医学综述,2013,19(19):3524-3526.
[28] Jamborova G,Pospisilova N,Semecky V,et al. Microdispersedoxidizedcelluloseas anovel potential substance withhypolipidemic properties.Nutrition.2008; 24: 1174-1181.
[29] Alfieri S,Di Miceli D,Menghi R,et al.Ｒole of oxidized regenerated cellulose in preventing infections at the surgical site: prospective，randomized study in 98 patients affected by a dirty wound.Minerva Chir.2011;66(1):55-62.
[30] Krízov P,Msov L,Suttnar J,et al.The influence of intrinsic coagulation pathway on blood platelets activation by oxidized cellulose.J Biomed Mater Res A.2007;82(2):274-280.
[31] Chapman WC,Singla N,Genyk Y,et al.A phase 3，randomized，double－blind comparative study of the efficiency and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis.Am Coll Surg. 2007; 205:256-265.
[32] Crean S,Michels S,Moschella K,et al.Bovine thrombin safety reporting: an example of study design and publication bias. Surg Res.2010;158:77-86.
[33] Karkouti K,Beattie WS.Aprotinin is useful as a hemostatic agent in cardiopulmonary surgery: no.J Thromb Haemost. 2006;4(9):1879-1881.
[34] Achneck HE,Sileshi B,Jamiolkowski RM,et al.A comprehensive review of topical hemostatic agents: efficacy and recommendations for use.Ann Surg.2010;251(2): 217-228.
[35] Kuphasuk W,Harnirattisai C,Senawongse P,et al.Bond strengths of two adhesive systems to dentin contaminated with a hemostatic agent.Oper Dent.2007;32(4): 399-405.
[36] Kinoshita Y,Matsuo M,Todoki K,et al.Alveolar bone regeneration using absorbable poly(L-lactide-co-epsilon- caprolactone)/beta-tricalcium phosphate membrane and gelatin sponge incorporating basic fibroblast growth factor.Int J Oral Maxillofac Sur.2008;37(3): 275-281.
[37] Suzuki Y,Vellinga TT,Istre O,et al．Small bowel obstruction associated with use of agelatin-thrombin matrix sealant( FloSeal) after laparoscopic gynecologic surgery.J MinimInvasive Gynecol.2010;17(5):641-645．
[38] Tirindelli MC,Flammia G,Sergi F,et al.Fibrin glue for refractory hemorrhagic cystitis after unrelated marrow，cord blood，and haploidentical hematopoietic stem cell transplantation. Transfusion.2009;49(1):170-175．
[39] 王平瑜,白雪峰,王保卫,等.人纤维蛋白胶对人肝损伤的止血护创作用［J].中国医学创新,2011,8(6):9-11．
[40] Millner RW,Lockhart AS,Bird H,et al.A new hemostatic agent: initial life－saving experience with Celox( chitosan) in cardiothoracic surgery.Ann Thorac Surg.2009;87:e13-e14．
[41] Xie H,Jeffrey ST,Burke AP,et al.Laparoscopic repair of inferior vena caval injury using a chitosan-based hemostatic dressing. Am J Surg.2009;197(4):510-514.